• For full details of graphics available/in preparation, see Menu -> Planners
Graphic toont het aandeel Bayer en een tijdlijn van jury-uitspraken over Bayers op glyfosaat gebaseerde onkruidverdelgers.
GN39118NL

BUSINESS

Aandeel Bayer keldert na kankerschandaal

May 15, 2019 - Negatieve jury-uitspraak heeft meer dan 40% van de marktwaarde van Bayer weggevaagd sinds augustus 2018, nu de Duitse farmaciegroep de schades door zijn op glyfosaat gebaseerde onkruidverdelger moet betalen.

A jury in California on Monday awarded more than $2bn to a couple who said the weedkiller Roundup was responsible for their cancer.

It is the third time that the German pharmaceutical group Bayer has been ordered to pay damages over its glyphosate-based herbicide.

Bayer, which acquired Roundup maker Monsanto for $63 billion last year, denies the allegations, saying decades of studies and regulatory approvals have shown glyphosate and Roundup to be safe for human use.

But the company faces similar U.S. lawsuits by more than 13,400 plaintiffs and shareholders have rebuked Bayer’s top management over its handling of the Monsanto acquisition and the litigation it inherited.

Sources
PUBLISHED: 15/05/2019; STORY: Graphic News; PICTURES: Getty Images
Advertisement